男性下尿路症状的新兴微创治疗选择
本文为叙述性综述,检索Medline、PubMed、Cochrane和Embase中关于良性前列腺增大所致男性下尿路症状(LUTS)新兴微创治疗的随机对照试验、临床试验和综述。结论认为多数新技术尚处早期,仅前列腺尿道提升术具有1级证据并可推荐用于经选择的患者。
要点
- PRX302是唯一在3期随机对照试验中优于安慰剂的候选前列腺内注射药物。
- 前列腺尿道提升术在多项3期试验中显示快速持久的LUTS缓解且不损害性功能。
- 前列腺动脉栓塞术技术成功率高,但存在相当比例的临床失败率和特有并发症。
核心结论
- 新兴微创治疗的初步临床结果令人鼓舞,疗效与标准技术相当,常伴有更有利的安全性,尤其是保留性功能。
- 许多技术尚处早期阶段,需要进一步随机对照试验评估疗效、安全性和持久性,并进行长期随访和仔细评估选择标准。
- 前列腺尿道提升术是唯一具有1级证据数据、因此可推荐用于临床实践中经选择的男性LUTS患者的技术。
研究设计与样本
- 叙述性综述,检索Medline、PubMed、Cochrane数据库和Embase中的随机对照试验、临床试验和综述。
主要发现
- PRX302是当前唯一在3期随机对照试验中显示优于安慰剂并提供疗效和安全性证据的前列腺内注射药物。
- 前列腺尿道提升术在多项3期试验中显示,对于无显著中叶且经仔细选择的患者,可快速持久缓解LUTS而不损害性功能。
- 临时可植入镍钛装置的首个临床经验表明植入安全、简单且快速,但需进一步研究评估疗效、持久性并确定合适患者选择。
- 图像引导机器人水刀消融(AquaBeam)和基于对流蒸汽能量(Rezūm)的消融方法处于早期开发阶段。
- 由介入放射科医生在专科中心进行的前列腺动脉栓塞术治疗烦人LUTS的技术成功率高,但存在相当比例的临床失败率和泌尿科干预后不常见的特有并发症。
关键数值与推荐
- 前列腺尿道提升术是唯一具有1级证据数据、可推荐用于临床实践中经选择的男性LUTS患者的技术。
临床怎么用
- 前列腺尿道提升术可推荐用于经选择的男性LUTS患者。
- 其他新技术在推荐作为标准手术替代之前仍需长期临床评估。
局限性
- 许多技术尚处早期阶段。
- 需要进一步随机对照试验评估新技术的疗效、安全性和持久性,并进行长期随访和仔细评估选择标准。
- 大多数创新技术仍需长期临床评估才能推荐作为标准手术的有效替代。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Lower urinary tract symptoms (LUTS) are one of the most common and troublesome nonmalignant conditions affecting quality of life in aging men. A spectrum of established medical and surgical options is available to provide relief of bothersome LUTS. Both the adverse events of medication and the morbidity with surgical treatment modalities have to be counterbalanced against efficacy. Novel minimally invasive treatment options aim to be effective, ideally to be performed in an ambulatory setting under local anaesthesia and to offer a more favourable safety profile than existing reference techniques. OBJECTIVE: A comprehensive, narrative review of novel minimally invasive treatment modalities for the management of male LUTS due to benign prostatic enlargement is presented. EVIDENCE ACQUISITION: Medline, PubMed, Cochrane database, and Embase were screened for randomised controlled trials (RCTs), clinical trials, and reviews on novel minimally invasive treatment options for male LUTS due to benign prostatic enlargement. EVIDENCE SYNTHESIS: With regard to newly devised intraprostatic injectables (botulinum neurotoxin A, NX1207, PRX302), PRX302 is currently the only substance that was superior to placebo in a phase 3 RCT providing proof of efficacy and safety. The prostatic urethral lift technique has been evaluated in several phase 3 trials showing rapid and durable relief of LUTS without compromising sexual function in carefully selected patients without a prominent median lobe. The first clinical experience of the temporary implantable nitinol device demonstrated that implantation of this novel device is a safe procedure, easy, and fast to perform. Further studies are required to evaluate efficacy, durability, and to define appropriate patient selection. New ablative approaches like the image guided robotic waterjet ablation (AquaBeam) or procedures based on convective water vapour energy (Rezūm) are in the early stages of development. Prostatic artery embolization performed by interventional radiologists at specialised centres shows a high technical success rate in the treatment of bothersome LUTS. However, a substantial clinical failure rate and a particular spectrum of complications not commonly seen after urologic interventions do occur and need to be critically evaluated. CONCLUSIONS: Initial promising clinical results on novel minimally invasive treatment options indicate efficacy comparable to standard techniques, often associated with a more favourable safety profile, in particular with preservation of sexual function. Many of these techniques are in their infancy and based on experience of new developments in the past. Further RCTs are required to evaluate efficacy, safety, and durability of novel techniques with long-term follow-up and careful evaluation of the selection criteria, which have been applied in clinical trials. The prostatic urethral lift is the only procedure with Level 1 evidence data and that can therefore be recommended for treatment of male LUTS in clinical practice for selected patients. PATIENT SUMMARY: Minimally invasive treatment options have been developed to provide relief of lower urinary tract symptoms comparable to standard surgical techniques with a more favourable safety profile. However, long-term clinical evaluation is still needed for most of these innovations before they can be recommended to be an effective replacement for standard surgical treatment.
引用
- Magistro G, Chapple CR, Elhilali M, et al. Emerging Minimally Invasive Treatment Options for Male Lower Urinary Tract Symptoms. Eur Urol. 2017. PMID: 28734706. doi:10.1016/j.eururo.2017.07.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。